FINWIRES · TerminalLIVE
FINWIRES
Novo Nordisk

Novo Nordisk

$NVO
NYSEPharmaceuticals

93 stories mentioning Novo NordiskUpdated 6d ago

A drugmaker in focus as CMS proposed a permanent Medicare drug-price-negotiation framework from 2029, while healthcare stocks rose.

Asia Markets

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

European equities traded in the US as American depositary receipts started the week higher late Monday morning, advancing 0.61% to 1,903.57 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by pharmaceutical company Novo Nordisk (NVO) and telecommunications company Nokia (NOK), which rose 4.5% and 4.2% respectively. They were followed by internet browser company Opera (OPRA) and biopharmaceutical company DBV Technologies (DBVT), which were up 2.8% and 1.8% respectively.The decliners from continental Europe were led by biopharmaceutical company Cellectis (CLLS) and pharmaceutical company Sanofi (SNY), which fell 5% and 2.8% respectively. They were followed by internet advertising firm Criteo (CRTO) and semiconductor company Sequans Communications (SQNS), which were down 2.6% and 2.4% respectively.The gainers from the UK were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Amarin (AMRN), which advanced 5.7% and 4.6% respectively. They were followed by lenders Lloyds Banking Group (LYG) and Barclays (BCS), which increased 4% and 3.8% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and mining company BHP Group (BHP), which lost 3.1% and 2% respectively. They were followed by telecommunications operator Vodafone Group (VOD) and medical device maker Smith & Nephew (SNN), which dropped 1.8% and 0.8% respectively.

$AMRN$BCS$BHP$CLLS$CRTO$DBVT$LYG$NCNA$NOK$NVO$OPRA$SLN$SNN$SNY$SQNS$VOD
Sectors

Sector Update: Healthcare Stocks Retreat Late Afternoon

Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index falling 1.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1.8%.The iShares Biotechnology ETF (IBB) rose 0.7%.In corporate news, ResMed (RMD) shares fell 4.5% after Morgan Stanley downgraded the company to equalweight from overweight and cut its price target to $230 from $286.UniQure (QURE) shares surged 76% after the company said that it intends to submit a Biologics License Application for the accelerated approval of AMT-130 to treat Huntington's disease in Q3.Novo Nordisk (NVO) said it is aware of claims by cyber extortion group FulcrumSec that it stole company data and sought a $25 million payment, Reuters reported. Novo shares were up 0.2%.Moderna (MRNA) plans to invest in production sites in Germany and is interested in the plants that BioNTech (BNTX) has slated for closure, according to a Google translation of a Wednesday report from German news outlet Handelsblatt. Moderna shares jumped almost 11%, and BioNTech was up 2.3%.

$BNTX$MRNA$NVO$QURE$RMD
Wire

Sector Update: Healthcare Stocks Decline Wednesday Afternoon

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index decreasing 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) rose 2.2%.In corporate news, IQVIA (IQV) shares fell 3.3% after Morgan Stanley downgraded the company to equalweight from overweight and cut its price target to $200 from $225.Novo Nordisk (NVO) said it is aware of claims by cyber extortion group FulcrumSec that it stole company data and sought a $25 million payment, Reuters reported. Novo shares were up 1.8%.Moderna (MRNA) plans to invest in production sites in Germany and is interested in the plants that BioNTech (BNTX) has slated for closure, according to a Google translation of a Wednesday report from German news outlet Handelsblatt. Moderna shares jumped past 8%, and BioNTech was up 4%.

$BNTX$IQV$MRNA$NVO
Sectors

Sector Update: Healthcare Stocks Mixed Premarket Wednesday

Healthcare stocks were mixed premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) 0.1% higher.Novo Nordisk (NVO) said it is aware of claims by cyber extortion group FulcrumSec that it stole company data and sought a $25 million payment, Reuters reported. Shares of Novo Nordisk were up more than 3% pre-bell.uniQure (QURE) stock was up more than 66% after the company said it intends to submit a Biologics License Application for the accelerated approval of AMT-130 to treat Huntington's disease in Q3.Jazz Pharmaceuticals (JAZZ) and AbCellera Biologics (ABCL) signed a preclinical research collaboration, option and license deal to discover and develop T-cell engaging multispecific antibodies, the companies said. Shares of AbCellera Biologics were up more than 2% and Jazz Pharmaceuticals stock was over 1% higher premarket.

$ABCL$IBB$JAZZ$NVO$QURE$XLP
Sectors

Sector Update: Healthcare

Healthcare stocks were mixed premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) 0.5% higher.Novo Nordisk (NVO) said it is aware of claims by cyber extortion group FulcrumSec that it stole company data and sought a $25 million payment, Reuters reported. Shares of Novo Nordisk were up more than 3% pre-bell.

$NVO
Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks edged higher Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 0.2%.The iShares Biotechnology ETF (IBB) was down 0.2%.In corporate news, GSK (GSK) said Health Canada approved Exdensur for severe eosinophilic asthma, which is driven by elevated white blood cells, and for chronic rhinosinusitis with nasal polyps, a condition that causes blockage and inflammation. GSK shares rose 0.3%.Novo Nordisk (NVO) plans to apply for Chinese regulatory approval of its oral weight-loss drug, Wegovy, within the next few months, Reuters reported, citing Chief Executive Mike Doustdar. According to the report, Eli Lilly (LLY) submitted a marketing application in China for its oral obesity drug late last year, putting the company ahead of Novo in the race to launch a weight-loss pill in the country. Novo shares were down 0.3%, and Lilly was 0.1% lower.Oncolytics Biotech (ONCY) shares jumped past 10% after it said Tuesday it has received a US patent covering the pelareorep manufacturing process into 2044.

$GSK$LLY$NVO$ONCY
Wire

CMS Proposes Permanent Framework for Medicare Drug Price Negotiation Program

The Centers for Medicare & Medicaid Services on Friday proposed a rule to establish a permanent regulatory framework for the Medicare Drug Price Negotiation Program beginning with the 2029 price applicability year, transitioning from implementation through annual guidance to codified regulations.The proposal would govern future negotiations and renegotiations for high-cost, single-source drugs covered under Medicare Part D and Part B. CMS said it will select up to 20 additional negotiation-eligible drugs for the fourth cycle of negotiations and future cycles of the program.The rule also proposes a temporary pricing floor for certain small biotech drugs in 2029 and 2030.CMS said it has negotiated prices for 25 high-expenditure drugs during the program's first two years. Maximum fair prices for the first 10 selected drugs took effect Jan. 1, 2026.Price: $236.56, Change: $-4.31, Percent Change: -1.79%

$ABBV$JNJ$LLY$MRK$NVO
Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 3%.In corporate news, Adial Pharmaceuticals (ADIL) shares surged 45% after it said Thursday it has acquired Azora Therapeutics, a biopharmaceutical company developing treatments for serious inflammatory diseases.Novartis (NVS) shares gained 4.2% after the company said a phase 1/2 trial of its experimental treatment del-brax met both primary and key secondary endpoints in people with facioscapulohumeral muscular dystrophy.Novo Nordisk (NVO) won approval from UK regulators for its Wegovy pill, a daily oral version of semaglutide, for weight management in adults with obesity or overweight and a weight-related condition. Novo shares rose 2.8%.Some employers in the US intend to drop coverage of GLP-1 medications for weight loss in 2027 amid the increasing popularity of Novo Nordisk's Wegovy and Eli Lilly's (LLY) Zepbound and Foundayo, Reuters reported, citing the Business Group on Health, a policy research group for large employers. Lilly shares were up 2.9%.

$ADIL$LLY$NVO$NVS
Sectors

Sector Update: Healthcare Stocks Rise Thursday Afternoon

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index adding 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.5%.The iShares Biotechnology ETF (IBB) climbed 1.9%.In corporate news, Novartis (NVS) shares gained 2.9% after the company said a phase 1/2 trial of its experimental treatment del-brax met both primary and key secondary endpoints in people with facioscapulohumeral muscular dystrophy.Novo Nordisk (NVO) won approval from UK regulators for its Wegovy pill, a daily oral version of semaglutide, for weight management in adults with obesity or overweight and a weight-related condition. Novo shares rose 1.2%.Some employers in the US intend to drop coverage of GLP-1 medications for weight loss in 2027 amid the increasing popularity of Novo Nordisk's Wegovy and Eli Lilly's (LLY) Zepbound and Foundayo, Reuters reported, citing the Business Group on Health, a policy research group for large employers. Lilly shares were up 1.5%.

$LLY$NVO$NVS
Wire

Novo Nordisk Reports Cybersecurity Incident Involving IT System Access

Novo Nordisk (NVO) said Thursday it identified an information technology security incident involving unauthorized access to a limited number of internal systems.The company has launched an investigation with external cybersecurity experts and is working with relevant authorities.Novo Nordisk has also taken certain internal systems offline as a precaution and is restoring them in a controlled manner. Core business operations remain unaffected and continue to run normally, according to the company.Preliminary findings show that certain non-public data, including personal information, were copied externally without authorization.Price: $43.30, Change: $+0.48, Percent Change: +1.13%

$NVO
Wire

Novo Nordisk Wins UK Approval for Wegovy Weight-Loss Pill

Novo Nordisk (NVO) won approval from UK regulators for its Wegovy pill, a daily oral version of semaglutide, for weight management in adults with obesity or overweight and a weight-related condition.The approval was based on data from a Phase 3 trial, Novo Nordisk said Thursday in a statement. Patients receiving semaglutide tablets achieved average weight loss of 13.6% after 64 weeks, compared with 2.4% for those receiving placebo, alongside lifestyle modifications, the company said.The UK is the first country in Europe to approve the medicine, which Novo Nordisk expects to make available via private prescription within weeks, the company said. The approval follows similar decisions in the US and the United Arab Emirates..Price: $43.41, Change: $+0.59, Percent Change: +1.39%

$NVO
Wire

Street Color: Novo Nordisk's Wegovy Gets UK Approval for Obesity Treatment

Street Color: Novo Nordisk's Wegovy Gets UK Approval for Obesity Treatment

$NVO
Wire

Market Chatter: Some US Employers Plan to Drop GLP-1 Coverage for Obesity in 2027

Some employers in the US intend to drop coverage of GLP-1 medications for weight loss in 2027 amid the increasing popularity of Novo Nordisk's (NVO) Wegovy and Eli Lilly's (LLY) Zepbound and Foundayo, Reuters reported Thursday, citing the Business Group on Health, a policy research group for large employers.Around 10% of employers who now cover GLP-1 drugs for weight-loss said they are planning to drop that coverage next year, the report said, citing the policy research group.Novo Nordisk and Eli Lilly didn't immediately reply to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $43.51, Change: $+0.72, Percent Change: +1.68%

$LLY$NVO
Wire

Some US Employers Plan to Drop GLP-1 Coverage for Obesity in 2027, Reuters Reports

Some US Employers Plan to Drop GLP-1 Coverage for Obesity in 2027, Reuters Reports

$LLY$NVO
Asia Markets

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

European equities traded in the US as American depositary receipts kicked off the week higher late Monday morning, lifting 0.82% to 1,874.41 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by semiconductor company Sequans Communications (SQNS) and biotech firm Evaxion (EVAX), which rose 7% and 4.5% respectively. They were followed by accommodations booking company trivago (TRVG) and telecommunications company Nokia (NOK), which increased 4.4% and 1.7% respectively.The decliners from continental Europe were led by pharmaceutical company Novo Nordisk (NVO) and biopharmaceutical company Cellectis (CLLS), which fell 2.9% and 2.3% respectively. They were followed by pharmaceutical company Sanofi (SNY) and biopharmaceutical company Grifols (GRFS), which were down 2% each.The gainers from the UK were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and NuCana (NCNA), which advanced 4.5% and 3.3% respectively. They were followed by oil and gas company BP (BP) and biopharmaceutical company Amarin (AMRN), which were up 1.7% and 1.6% respectively.The decliners from the UK and Ireland were led by biotech company Autolus Therapeutics (AUTL) and biopharmaceutical company Mereo BioPharma Group (MREO), which dropped 4.2% and 2.4% respectively. They were followed by utilities company National Grid (NGG) and pharmaceutical company GSK (GSK), which lost 2% and 1.2% respectively.

$AMRN$AUTL$BDRX$BP$CLLS$EVAX$GRFS$GSK$MREO$NCNA$NGG$NOK$NVO$SNY$SQNS$TRVG
Wire

Veru Enters Supply Agreement With Novo Nordisk for Obesity Study; Shares Surge

Veru (VERU) said Thursday in a regulatory filing that it entered a clinical supply agreement with Novo Nordisk (NVO) to support its phase 2b PLATEAU study evaluating enobosarm in combination with Novo's Wegovy in older adults with obesity undergoing weight loss treatment.Under the agreement, Novo Nordisk will provide Wegovy free of charge for the study, while Veru will sponsor and conduct the trial and share clinical study updates and insights related to obesity and weight management research, the filing shows.Veru said it retains global development and commercialization rights to enobosarm, while Novo Nordisk received a right of first negotiation if Veru seeks to develop, commercialize or license enobosarm in combination with Novo Nordisk GLP-1 products in the future.Shares of Veru rose 155% in Thursday trading.Price: $5.52, Change: $+3.27, Percent Change: +145.47%

$NVO$VERU
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index shedding 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.7%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Cigna (CI) shares fell 1.6% after Barclays downgraded the stock to equalweight from overweight, and lowered its price target to $304 from $310.Brazil on Tuesday cleared pharmaceutical company EMS to sell the country's first generic version of Novo Nordisk's (NVO) Ozempic shot, Bloomberg reported. EMS plans to sell the generic version, called Ozivy, for 30% less than Ozempic, and it expects it to hit the market within 30 days, the report said. Novo shares were down 1.5%.Eli Lilly (LLY) said it has struck deals to buy three vaccine developers in all-cash deals with a combined value of up to $3.83 billion to build its infectious disease portfolio. Lilly shares rose 0.5%.CG Oncology (CGON) shares fell 3.8% after the firm said that Ambaw Bellete, its president and chief operating officer, will exit the company, effective June 30.

$CGON$CI$LLY$NVO
Sectors

Sector Update: Healthcare Stocks Decline Tuesday Afternoon

Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.5%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Brazil on Tuesday cleared pharmaceutical company EMS to sell the country's first generic version of Novo Nordisk's (NVO) Ozempic shot, Bloomberg reported. EMS plans to sell the generic version, called Ozivy, for 30% less than Ozempic, and it expects it to hit the market within 30 days, the report said. Novo shares were down 1.4%.Eli Lilly (LLY) said it has struck deals to buy three vaccine developers in all-cash deals with a combined value of up to $3.83 billion to build its infectious disease portfolio. Shares rose 1.3%.CG Oncology (CGON) shares declined 2.9% after the firm said that Ambaw Bellete, its president and chief operating officer, will exit the company, effective June 30.BioRestorative Therapies (BRTX) shares jumped 18% after the firm said it has completed dosing in its phase 2 trial assessing BRTX-100 to treat chronic lumbar disc disease.

$BRTX$CGON$LLY$NVO
Sectors

Sector Update: Healthcare

Healthcare stocks declined Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.5%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Brazil on Tuesday cleared pharmaceutical company EMS to sell the country's first generic version of Novo Nordisk's (NVO) Ozempic shot, Bloomberg reported. EMS plans to sell the generic version, called Ozivy, for 30% less than Ozempic, and it expects it to hit the market within 30 days, the report said. Novo shares were down 1.4%.

$NVO
Asia Markets

European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading

European equities traded in the US as American depositary receipts were trending higher late Tuesday morning, rising 0.73% to 1,891.94 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by accommodations booking site trivago (TRVG) and telecommunications company Nokia (NOK), which rose 6.4% and 4.8% respectively. They were followed by lenders Banco Bilbao Vizcaya Argentaria (BBVA) and Banco Santander (SAN), which were up 4.4% and 3.8% respectively.The decliners from continental Europe were led by pharmaceutical company Ascendis Pharma (ASND) and petroleum refiner Equinor (EQNR), which fell 3% and 2% respectively. They were followed by internet advertising firm Criteo (CRTO) and pharmaceutical company Novo Nordisk (NVO), which were down 1.1% and 0.2% respectively.The gainers from the UK were led by biopharmaceutical company Mereo BioPharma Group (MREO) and pharmaceutical company Silence Therapeutics (SLN), which climbed 16% and 6.3% respectively. They were followed by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which advanced 4.5% and 3.1% respectively.The decliners from the UK and Ireland were led by oil and gas company BP (BP) and biopharmaceutical company NuCana (NCNA), which dropped 5% and 2.4% respectively. They were followed by biopharmaceutical company Amarin (AMRN) and communications company WPP (WPP), which lost 1.6% and 1.5% respectively.

$AMRN$ASND$BBVA$BDRX$BP$CRTO$EQNR$MREO$NCNA$NOK$NVO$SAN$SLN$TRIB$TRVG$WPP

Showing 21-40 of 93

Track with the FINWIRES app suite

FolioX
FolioX
Track Novo Nordisk in your portfolio
WheelAI
WheelAI
Analyze Novo Nordisk options with the wheel strategy
StockInsider
StockInsider
See market sentiment on Novo Nordisk